OKYO Pharma LimitedNASDAQ: OKYO

OKYO Pharma Announces Purchase of Shares by Director

· Issued by OKYO Pharma Limited via GlobeNewswire

Summary by 6ix AI

OKYO Pharma Limited, a clinical-stage drug developer working on treatments for neuropathic corneal pain (nerve-related eye surface pain) and diseases of the front of the eye, said Non-Executive Director John Brancaccio bought 5,000 of its ordinary shares on Nasdaq at $1.48 per share.

Key details

  • The purchase brings John Brancaccio's total holding to 35,201 shares.

6ix AI wrote this summary from the release below and checked it against the release.

LONDON and NEW YORK, July 23, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced that OKYO Pharma's Non-Executive Director, John Brancaccio has purchased 5,000 of the Company's ordinary shares on NASDAQ at $1.48 per share, bringing his total holding to 35,201 shares.

About OKYO Pharma

OKYO Pharma Limited (Nasdaq: OKYO) is a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, with ordinary shares listed for trading on the Nasdaq Capital Market. OKYO plans to initiate a global Phase 3 pivotal clinical trial in the second half of this year, enrolling approximately 111 patients to evaluate a single-dose regimen of urcosimod for the treatment of NCP.

For further information, please visit www.okyopharma.com.

For further inquiries:

OKYO Pharma Ltd
Paul Spencer
Business Development and Investor Relations
+44 (0) 207 495 2379
Email: [email protected]

OKYO Pharma Limited on 6ix

Story so far

Earlier from OKYO Pharma

Later from OKYO Pharma

All OKYO Pharma news releases